1. Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
- Author
-
Howard OM, Talpaz M, Kantarjian H, Seong D, Wedrychowski A, Paslidis N, Hester J, Cork A, Turpin J, and Lopez-Berestein G
- Subjects
- Base Sequence, Blood Cells analysis, Blood Cells cytology, Bone Marrow analysis, Bone Marrow Cells, Humans, Injections, Subcutaneous, Interferon Type I administration & dosage, Interferon Type I metabolism, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Molecular Sequence Data, Nuclear Proteins genetics, Nuclear Proteins metabolism, Oligonucleotides genetics, Transcription Factors analysis, Transcription Factors genetics, Transcription Factors metabolism, Interferon Type I pharmacology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Nuclear Proteins analysis
- Abstract
Cytoplasmic protein extracts from chronic myelogenous leukemia (CML) cells contained an activity that altered the electrophoretic mobility of complexes formed between nuclear proteins and the transcriptional enhancers of interferon (IFN)-inducible genes. Exposure of CML cells to IFN-alpha diminished the effect of the CML cytoplasmic proteins on these nuclear protein-DNA complexes. The presence of clinical responsiveness to IFN-alpha correlated with the sensitivity to the IFN-induced change in the electrophoretic mobility of nuclear protein-DNA complexes. These data suggest that the action of IFN-alpha in CML may be linked to a pathway that can result in posttranslational modification of nuclear proteins.
- Published
- 1990